Sensorion Announces its Participation in the Annual Bioprocessing Summit Europe
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the Bioprocessing Summit Europe, taking place on March 19-21, 2024, in Barcelona, Spain.
- Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the Bioprocessing Summit Europe, taking place on March 19-21, 2024, in Barcelona, Spain.
- Christine Le Bec, PhD, Head of CMC Gene Therapy, will chair a session entitled “Advancing Technical Development of Gene Therapies”, on March 19, 2024, at 8.25am CET (3.25am EDT).
- Christine will also make the following presentation “Manufacturing Challenges and Control Strategies for Dual AAV Vectors”, on March 19, 2024, at 2.50pm CET (9.50am EDT).